IMV Inc IMVIF

DPX platform deal about to be closed

[Biotech010]

I spoke with the company in the last weeks a few times. There is a lot of interest from a wide range of companies in the DPX platform. They are now at the point where the economics of the deal are on the table... so how much upfront / % of further sales etc.... 

I'm very confident they will deliver deals very soon.

[antigua1987]

Thanks Bio - do you have any other biotech investments where you've had success such as you're predicting now for IMV? Not throwing stones here, but IMV seems to be only stock you're following on SH.

[Jthom376]

Investments going to be touching $1.20 and lower is they don't have something really exciting.  As it stands, even their Q1 2022 DLBCL update is off the table as they've never dosed first patient. If that occurs, it will head to sub $1. Strange company... oh well still holding $6 average! lol

[Biotech010]

They have people in line waiting to get the first dose but those ppeople / patients have to meet certain criteria to enter the trial. The first patient can be dosed any day now.